User:Sonnemed

Activated Therapy is a novel, non-toxic approach for the amelioration of cancer. In activated therapy, a non-toxic therapeutic becomes cytopathogenic when activated by an external energy source including ultrasound or red light. The specific activated therapies are referred to as Ultrasound Activated Cancer Therapy (USAT) and Photodynamic Therapy (PDT). When these therapies are used in combination, it is referred to as the SonneLux Protocol or Sonodynamic-Photodynamic Therapy (SPDT).

SonneMed LLC in Boston, MA, holds the intellectual property to emerging activated therapeutics (sensitizers) that is used with the SonneLuxe Protocol. The sensitizers are non-toxic and have great specificity for malignant tissue. When activated, the sensitizers cause destruction to cancer cells only and do not impact healthy tissue. The efficacy of the SonneLux Protocol is demonstrated most profoundly through results from mouse, zebra fish studies and clinical trials. Further, the mechanism of tumor cell destruction is necrosis instead of apoptosis. A “vaccine” effect has been noted.